Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Funda Meric‐Bernstam, John D. Hainsworth, Robert R. McWilliams et al.|The Lancet Oncology|2019

Cited by 564